Profile data is unavailable for this security.
About the company
Zenas BioPharma, Inc. is a clinical-stage global biopharmaceutical company. The Company is focused on the development and commercialization of immunology-based therapies for patients in need. Its lead immunology and inflammation (I&I) product candidate, obexelimab, is a bifunctional monoclonal antibody designed to bind both CD19 and FcyRIIb, which are broadly present across B cell lineage, to inhibit the activity of cells that are implicated in many autoimmune diseases without depleting them. It is developing obexelimab as a potential I&I franchise for patients in several autoimmune diseases. Its pipeline also includes two global programs, ZB002 (an anti-TNFα monoclonal antibody) and ZB004 (a CTLA-4-Ig fusion), and two regional programs, ZB001 (also known as VRDN-001, an IGF-1R monoclonal antibody), and related programs, and ZB005 (also known as DNTH103, an anti-active C1s monoclonal antibody), for which the Company hold the development and commercialization rights in greater China.
- Revenue in USD (TTM)50.00m
- Net income in USD-54.76m
- Incorporated2023
- Employees114.00
- LocationZenas Biopharma Inc1000 Winter St, Suite 1200WALTHAM 02451United StatesUSA
- Phone+1 (857) 271-2954
- Fax+1 (302) 655-5049
- Websitehttps://zenasbio.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Arbutus Biopharma Corp | 10.06m | -77.09m | 783.45m | 73.00 | -- | 6.40 | -- | 77.87 | -0.4416 | -0.4416 | 0.0575 | 0.6488 | 0.0597 | -- | 4.59 | 137,821.90 | -45.77 | -52.62 | -53.21 | -58.11 | -- | -- | -766.20 | -537.81 | -- | -- | 0.00 | -- | -53.51 | 25.00 | -4.89 | -- | -2.40 | -- |
Replimune Group Inc | 0.00 | -220.01m | 787.75m | 331.00 | -- | 1.85 | -- | -- | -3.27 | -3.27 | 0.00 | 6.24 | 0.00 | -- | -- | 0.00 | -38.64 | -29.08 | -41.09 | -30.56 | -- | -- | -- | -- | -- | -- | 0.143 | -- | -- | -- | -23.82 | -- | 16.84 | -- |
Annexon Inc | 0.00 | -115.16m | 790.29m | 71.00 | -- | 2.19 | -- | -- | -1.22 | -1.22 | 0.00 | 3.42 | 0.00 | -- | -- | 0.00 | -36.04 | -44.06 | -38.13 | -46.93 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 5.43 | -- | 62.56 | -- |
Tango Therapeutics Inc | 42.51m | -116.49m | 799.30m | 140.00 | -- | 3.22 | -- | 18.80 | -1.11 | -1.11 | 0.4068 | 2.31 | 0.1118 | -- | -- | 303,635.70 | -30.62 | -- | -35.13 | -- | -- | -- | -274.04 | -- | -- | -- | 0.00 | -- | 46.93 | -- | 5.95 | -- | -- | -- |
BIOAGE Labs Inc | 0.00 | -62.16m | 815.23m | 58.00 | -- | -- | -- | -- | -1.82 | -1.82 | 0.00 | 4.26 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -4.99 | 0.0724 | -- | -- | -- | -60.75 | -- | -- | -- |
Erasca Inc | 0.00 | -158.28m | 822.09m | 126.00 | -- | 1.76 | -- | -- | -0.9207 | -0.9207 | 0.00 | 1.65 | 0.00 | -- | -- | 0.00 | -32.76 | -- | -34.48 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 48.50 | -- | -- | -- |
Nuvation Bio Inc | 1.44m | -510.72m | 833.60m | 167.00 | -- | 2.12 | -- | 580.91 | -2.11 | -2.11 | 0.0064 | 2.43 | 0.0023 | -- | 0.4216 | 28,137.26 | -82.63 | -16.27 | -87.18 | -16.65 | 6.13 | -- | -35,590.24 | -- | -- | -- | 0.0214 | -- | -- | -- | 27.25 | -- | -- | -- |
Silence Therapeutics plc | 23.36m | -52.32m | 839.41m | 115.00 | -- | 5.83 | -- | 35.94 | -0.4206 | -0.4206 | 0.1866 | 1.05 | 0.1273 | -- | 2.56 | 203,106.60 | -28.51 | -43.60 | -32.89 | -54.91 | 56.40 | -- | -224.01 | -287.30 | -- | -- | 0.0016 | -- | 44.99 | -- | -6.86 | -- | 156.10 | -- |
Capricor Therapeutics Inc | 27.15m | -27.95m | 843.88m | 101.00 | -- | 52.44 | -- | 31.08 | -0.9302 | -0.9302 | 0.9072 | 0.3596 | 0.6443 | -- | 59.18 | 268,833.90 | -66.31 | -54.12 | -208.71 | -75.13 | -- | -- | -102.93 | -316.25 | -- | -- | 0.2269 | -- | 886.81 | 72.02 | 23.20 | -- | 45.27 | -- |
AbCellera Biologics Inc | 33.06m | -153.30m | 845.69m | 586.00 | -- | 0.7612 | -- | 25.58 | -0.5254 | -0.5254 | 0.1133 | 3.77 | 0.0224 | -- | 0.808 | 56,407.85 | -10.39 | 6.08 | -11.11 | 6.67 | -- | -- | -463.77 | 24.69 | -- | -- | 0.00 | 0.00 | -92.17 | 33.91 | -192.35 | -- | 70.96 | -- |
Zenas Biopharma Inc | 50.00m | -54.76m | 849.17m | 114.00 | -- | -- | -- | 16.98 | -1.38 | -1.38 | 1.26 | 4.04 | -- | -- | -- | 595,238.10 | -- | -- | -- | -- | -- | -- | -109.51 | -- | -- | -- | 0.00 | -- | -- | -- | 68.88 | -- | -- | -- |
Perspective Therapeutics Inc | -1.87m | -49.02m | 852.96m | 116.00 | -- | 2.50 | -- | -- | -1.39 | -1.75 | -0.0437 | 5.06 | -0.0074 | -- | -- | -16,086.21 | -19.37 | -- | -20.14 | -- | -- | -- | -- | -- | -- | -- | 0.005 | -- | -- | -- | -- | -- | -- | -- |
Dianthus Therapeutics Inc | 4.12m | -56.68m | 853.09m | 53.00 | -- | 2.38 | -- | 207.16 | -5.54 | -5.54 | 0.2092 | 12.20 | 0.0184 | -- | -- | 77,698.11 | -25.33 | -41.40 | -26.15 | -44.70 | -- | -- | -1,376.42 | -12,132.27 | -- | -- | 0.00 | -- | -- | -- | 43.04 | -- | -57.21 | -- |
MiMedx Group Inc | 340.46m | 89.67m | 854.43m | 895.00 | 11.65 | 5.08 | 8.71 | 2.51 | 0.4996 | 0.4622 | 2.08 | 1.15 | 1.67 | 2.70 | 6.69 | 380,402.30 | 48.16 | -4.14 | 60.79 | -5.90 | 83.41 | 83.61 | 28.76 | -2.70 | 3.22 | 13.06 | 0.1028 | -- | 20.03 | -2.19 | 310.29 | -- | -26.47 | -- |
89bio Inc | 0.00 | -174.61m | 884.35m | 70.00 | -- | 1.70 | -- | -- | -1.97 | -1.97 | 0.00 | 4.91 | 0.00 | -- | -- | 0.00 | -32.50 | -45.50 | -34.68 | -49.31 | -- | -- | -- | -- | -- | -- | 0.0465 | -- | -- | -- | -39.37 | -- | -36.58 | -- |
Holder | Shares | % Held |
---|---|---|
Fairmount Funds Management LLCas of 16 Sep 2024 | 3.20m | 8.04% |
Wellington Management Co. LLPas of 16 Sep 2024 | 801.62k | 2.02% |